Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor

这项试验是少数几项专门专注于将抗CD19 CAR T细胞应用于同种异体移植环境的CAR试验之一。这项试验意义重大，因为与大多数抗CD19嵌合抗原受体的试验不同，它不包括化疗，因此它对抗CD19 CAR T细胞的活性进行了纯粹的评估。我们将继续招募更多的患者参加这项试验。我们已经获得了重要的信息，毒性和预测成功的治疗与每一个病人。一篇涵盖本试验的论文（Brudno等人）2016年发表在《临床肿瘤学杂志》上。该项目现在专注于测试被称为干记忆T细胞（Ttscm）的分化程度较低的T细胞，这些细胞被抗CD19 CAR转导。在这项工作中，我们目前正在与另一位研究者Luca Gattinoni合作，开发一种用于施用同种异体抗CD19 CAR干记忆T细胞的方法。在这项临床试验中，我们用抗CD19 CAR Tscm细胞治疗了11名患者。1例急性淋巴细胞白血病患者在输注Tscm抗CD19 CAR T细胞后获得完全缓解，目前正在进行中。另一例淋巴瘤患者获得部分缓解。该试验现已结束入组，报告结果的手稿正在编写中。许多相关的免疫学实验正在进行中。

This trial is one of few CAR trials exclusively focused on applying anti-CD19 CAR T cells to the allogeneic transplantation setting. This trial is significant because unlike most trials of anti-CD19 chimeric antigen receptors, it does not include chemotherapy, so it gives a pure assessment of the activity of the anti-CD19 CAR T cells. We continue recruit more patients for this trial. We have obtained important information on toxicity and predictors of successful therapy with each patient. A paper covering this trial (Brudno et al.) was published in the Journal of Clinical Oncology in 2016. The project is now focused on testing less-differentiated T cells called stem memory T cells (Ttscm) transduced with an anti-CD19 CAR. In this effort, we are currently collaborating with another Investigator, Luca Gattinoni, in developing a process for administering allogeneic anti-CD19 CAR stem memory T cells. We have treated 11 patients with anti-CD19 CAR Tscm cells on this clinical trial. A patient, with acute lymphoid leukemia, obtained a complete remission after infusion of Tscm anti-CD19 CAR T cells that is ongoing. Another patient with lymphoma obtained a partial remission. This trial has now ended enrollment and a manuscript reporting the results is in preparation. Many correlative immunology experiments are in progress.